2024年底至2025年初,全球医药市场再起波澜。跨国制药巨头赛诺菲(Sanofi)宣布,将斥资约95亿美元现金、溢价34.21%(较过去30日均价)收购罕见病&自免生物技术公司BlueprintMedicines(BPMC)。这笔重磅交易也算是给赛诺菲未来的押注方向定了调:加速向罕见病、小分子抑制剂及自身免疫等高增长赛道倾斜,以应对达必妥(度普利尤单抗)专利到期后的增长乏力,并进一步巩固其行业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.